Stephanie Courson Pothoven, DO
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,559 of the $8,003 with a category attached, or 69.5%. 35 manufacturers reported payments, led by Medtronic at 52.9% of the total. 2025 is the largest year on record at $2,144, 2.6 times the $818 reported in 2019.
Across 140 payments — averaging $57.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- Boston Scientific$1K
- Coloplast$705
- AbbVie$315
- Johnson & Johnson$280
- Neotract Inc.$248
- plus $1K from 29 others
What the payments were for
- Travel & lodging$2,29529%
- Food & beverage$5,55969%
- Education$1492%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 45 | $4,232 |
| Boston Scientific | 14 | $1,047 |
| Coloplast | 11 | $705 |
| AbbVie | 10 | $315 |
| Johnson & Johnson | 9 | $280 |
| Neotract Inc. | 5 | $248 |
| Dornier Medtech America, Inc | 3 | $232 |
| Axonics, Inc. | 4 | $106 |
| Intuitive Surgical | 1 | $92 |
| KARL Storz Endoscopy-america | 2 | $78 |
| Olympus America Inc. | 3 | $74 |
| Novartis | 3 | $69 |
| Urogen Pharma, Inc. | 3 | $49 |
| Travere Therapeutics, Inc. | 2 | $40 |
| Verity Pharmaceuticals Inc. | 2 | $38 |
| Amgen | 2 | $35 |
| Procept Biorobotics Corporation | 1 | $33 |
| Astellas Pharma US Inc | 2 | $31 |
| Dendreon Pharmaceuticals LLC | 1 | $25 |
| AstraZeneca | 1 | $23 |
| Tolmar, Inc. | 1 | $22 |
| Bayer | 1 | $19 |
| Endo USA, Inc. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Myriad Genetic Laboratories, Inc. | 1 | $18 |
| Cook Medical LLC | 2 | $18 |
| Accord Healthcare, Inc. | 1 | $17 |
| Ferring Pharmaceuticals Inc. | 1 | $17 |
| Pfizer | 1 | $16 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $16 |
| Sun Pharmaceutical Industries Inc. | 1 | $16 |
| Teleflex LLC | 1 | $15 |
| Progenics Pharmaceuticals, Inc. | 1 | $14 |
| Merck | 1 | $14 |
| Valencia Technologies Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$2,086
- rezum Generator$149
- BOTOX$139
- ALTIS$128
- AMS$120
- Lithotripters & Accessories$119
- GENERAL ONCOLOGY$119
- REZUM$117
- GENERAL VASCULAR ACCESS$113
- Saffron$109
- GENERAL BPH$104
How this compares
$8,003 in reported general payments places this provider in the 80th percentile of 114 urology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 88 | $51,119 |
| GemtesaVibegron | 18 | $17,234 |
| Estradiol | 144 | $9,953 |
| Solifenacin Succinate | 87 | $2,429 |
| Oxybutynin Chloride ErOxybutynin Chloride | 102 | $1,794 |
| Desmopressin Acetate | 24 | $1,488 |
| Tamsulosin Hcl | 53 | $862 |
| Methenamine Hippurate | 14 | $678 |
| Finasteride | 21 | $229 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 51 | $105 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 11 | $99 |
| Ciprofloxacin Hcl | 49 | $94 |
| Oxybutynin Chloride | 16 | $77 |
| Levofloxacin | 12 | $15 |
| Oxycodone Hcl | 12 | $12 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $31 | $51,11988 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 114 urology providers in Iowa.
Other urology in Clive
- Ryan DornbierClive$55K
- Mark KellermanClive$14K
- Trevor WildClive$10K
- McCabe KennyClive$5K
- Brian GallagherClive$4K
- Jacob JippClive$3K
- Vignesh PackiamIowa City$112K
- Annah VollstedtIowa City$66K
- Bradley EricksonIowa City$65K
- Michael OdonnellIowa City$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.